stockrowAxoGen, Inc.
AXGN Healthcare Medical Devices
AxoGen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $225.2 million, up 20.2% from fiscal 2024.
- Revenue
- +26.2%
- EPS
- +163.2%
- Free cash flow
- +995.0%
- Total debt
- −73.1%
Quarter to September 2026, against a year earlier
Follow AXGN
Alert me
AxoGen, Inc. (AXGN) EPS (diluted)
AxoGen, Inc.'s EPS (diluted) for fiscal 2025 was −$0.34, compared with −$0.23 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$0.65. Over the past ten years it has ranged from −$0.74 (fiscal 2019) to −$0.23 (fiscal 2024); the current reading is higher than 82% of that period. AxoGen, Inc. ranks 70th of 147 Medical Devices companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$0.34 | — |
| FY2024 | −$0.23 | — |
| FY2023 | −$0.51 | — |
| FY2022 | −$0.69 | — |
| FY2021 | −$0.65 | — |
| FY2020 | −$0.60 | — |
| FY2019 | −$0.74 | — |
| FY2018 | −$0.60 | — |
| FY2017 | −$0.31 | — |
| FY2016 | −$0.47 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.04 | — |
| Jun 2026 | −$0.03 | — |
| Mar 2026 | −$0.38 | — |
| Dec 2025 | −$0.28 | — |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| UFPT UFP Technologies, Inc. compare | $9.81 |
| TMDX TransMedics Group, Inc. compare | $3.69 |
| INSP Inspire Medical Systems, Inc. compare | $3.44 |
| ITGR Integer Holdings Corporation compare | $2.98 |
| NEOG Neogen Corporation compare | −$0.25 |
| AXGN AxoGen, Inc. | −$0.65 |
| IRTC iRhythm Holdings, Inc. compare | −$1.17 |
| ESTA Establishment Labs Holdings Inc. compare | −$1.31 |
| ALMR Alamar Biosciences, Inc. compare | −$2.77 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on AXGN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement